Krystal Biotech to Present at 8th Annual Evercore Healthcare Conference
Rhea-AI Summary
Krystal Biotech (NASDAQ: KRYS) will participate in the 8th Annual Evercore Healthcare Conference on December 3, 2025 in Miami.
Krish S. Krishnan, Chairman and CEO, will appear in a fireside chat at 10:00 am ET and will host investor meetings throughout the day. A webcast of the presentation will be available beginning at 10:00 am ET on December 3, 2025 and will be posted in the Investors section of the company website.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, KRYS gained 0.80%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
KRYS gained 2.17% while close biotech peers showed mixed, mostly smaller moves (e.g., ARWR +2.85%, MTSR -0.34%), indicating a stock-specific tilt rather than a broad sector swing.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 26 | Investor conference | Neutral | +0.8% | Announcement of Evercore conference appearance and webcast access details. |
| Nov 03 | Earnings results | Positive | +0.2% | Reported Q3 2025 financial and operating results with VYJUVEK revenue detail. |
| Oct 21 | Earnings scheduling | Neutral | -2.6% | Set date and webcast for upcoming Q3 2025 financial results release. |
| Oct 14 | FDA designation | Positive | +1.8% | FDA granted platform technology designation for HSV-1 vector used in KB801. |
| Sep 15 | FDA approval update | Positive | +8.4% | FDA approved updated VYJUVEK label expanding eligibility and at-home use. |
KRYS has generally reacted positively to value-adding catalysts like FDA approvals and platform designations, with modest moves on routine conference or timing announcements and one notable spike on the VYJUVEK label update.
Over the last several months, KRYS has reported strong financial results and meaningful regulatory progress. Q3 2025 earnings on Nov 3 highlighted solid VYJUVEK revenue and margins, following an FDA-approved VYJUVEK label update on Sep 15 that expanded use to newborns and allowed at-home application. The FDA then granted platform technology designation for the HSV‑1 viral vector on Oct 14. Against this backdrop, today’s Evercore conference participation fits as routine investor-engagement activity.
Market Pulse Summary
This announcement outlines Krystal Biotech’s participation in the Evercore Healthcare Conference on December 3, 2025, including a 10:00 am ET fireside chat and investor meetings. It represents standard investor-relations activity rather than a new clinical or financial milestone. In context of recent FDA label and platform wins plus strong earnings, investors may watch for any incremental commentary on commercialization trends, pipeline timelines, or capital deployment during the conference webcast.
AI-generated analysis. Not financial advice.
PITTSBURGH, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the 8th Annual Evercore Healthcare Conference on December 3, 2025, in Miami. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 10:00 am ET and host investor meetings throughout the day.
A webcast of the presentation will be available here beginning at 10:00 am ET on Wednesday, December 3, 2025 and will be posted on the Investors section of the Company’s website.
About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK®, the Company’s first commercial product, is the first-ever redosable gene therapy and the first genetic medicine approved in the United States, Europe, and Japan for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).
CONTACT
Investors and Media:
Stéphane Paquette
Krystal Biotech
spaquette@krystalbio.com
FAQ
When will Krystal Biotech (KRYS) present at the Evercore Healthcare Conference?
What time is Krystal Biotech's (KRYS) fireside chat at the Evercore conference?
Will Krystal Biotech (KRYS) provide a webcast of its Evercore presentation?
Who will represent Krystal Biotech (KRYS) at the Evercore Healthcare Conference?
Where can investors watch Krystal Biotech's (KRYS) Evercore presentation replay?
